A new study led by Harvard Pilgrim Health Care Institute and Duke University researchers found that state policies intended to reduce insulin out-of-pocket (OOP) costs for commercially insured people were not associated with increased insulin use in the overall population. However, monthly insulin OOP costs declined substantially for members in high deductible health plans with health savings accounts, plans that generally require high insulin OOP payments.
This article was originally published on MedicalXpress.com
